INVO

INVO Bioscience (INVO) is an emerging growth company that owns the INVOcell system, an FDA cleared patented medical device that is one of only 3 ways today that a couple that is struggling with infertility may choose to use to try to get pregnant and that offers a more economical and natural way to proceed. Depending on what statistics that you review today, Industry forecasts suggest that no more than 10% of the estimated 150 million infertile couples worldwide are currently being treated. After further research, this severely underserved market has been created and left unaddressed primarily because of capacity constraints, access to care & the associated cost issues, which the INVOcell system is believed to be in prime position to address.

For many couples struggling with infertility, access to treatment is often unavailable. Financial challenges (i.e. cost of treatment) and limited availability (or capacity) of fertility medical care are two of the main challenges in the ART marketplace that contribute to the large percentage of untreated patients. Religious, social and cultural roadblocks can also prevent hopeful couples from realizing their dream to have a baby with conventional IVF. INVO believes INVOcell can address many of the key challenges in the ART market, particularly patient cost and infrastructure capacity constraints.

The many benefits of the INVO Solution include: 1. Cost: Current U.S.-based clinics offering INVOcell are doing so at approximately half the cost of IVF treatment, due to less drugs often being prescribed for INVOcell, fewer office visits and less laboratory time needed as incubation is occurring inside the body rather than a lab incubator. 2. Enhances Industry Capacity: The INVOcell device eliminates the need for a lab incubator as well as helps reduce the overall need for lab-support resources during the incubation period. We believe this generally supports the ability to lower costs as well as enable a clinic to handle a higher volume of patients. 3. Promotes greater involvement by couples in the treatment and conception. 4. Reduces the risk of errors of wrong embryo transfers since the embryos are never separated from the woman. 5. Creates a more natural and environmentally stable incubation than traditional IVF in the laboratory.

INVO Bioscience, the company, has been transforming over the last couple of years & relatively recently, under the relatively new leadership of CEO Steve Shum (joined as CEO Q4 2019), successfully conducted a public offering in November 2020, raising gross proceeds of $13 million at $3.20/share, while uplisting the company onto the NASDAQ market. These moves strengthened their balance sheet & their position to execute on their commercialization efforts in the US and around the world and helped improve the adoptability of investors and Wall Street alike.

INVO has also transformed their board of directors adding a couple of powerful global thought leaders including Barbara Ryan, a Corporate (Public) Board Member with expertise in Healthcare and Life Science Capital Markets – Audit -Strategic Counselor to CEO/C-Suite within Biopharma & Med-Tech with 31 Years of experience working on Wall Street as Pharmaceutical Analyst and Managing Director and a frequent guest expert on CNBC. INVO also recently added Rebecca Messina. Messina has broad international experience in leading marketing for elite brands and businesses including Uber Technologies (UBER), Beam Suntory and The Coca-Cola Company (KO). She is currently a Senior Advisor at McKinsey & Company focused on advising internal teams and firm clients in the areas of marketing as a growth lever, including data driven marketing, brand building, and strategically shaping and transforming marketing agendas.

INVO has also recently developed a Scientific Advisory Board of four members with deep industry knowledge, where 2 of of them have become joint venture partners seeking to open INVOcell-only clinics in the US and Mexico in the early part of the second half of 2021. 

INVO is pushing forward with a combined distribution partner and joint venture model to accelerate their business worldwide. They now have structured distribution agreements in eight countries located within Africa, Asia, Europe, and the Middle East. INVO has also structured additional joint venture agreements to open their first INVOcell-exclusive clinics in Birmingham, AL (March 15, 2021) & San Francisco Bay Area (April 19) and Mexico (September 30, 2020) where they will share not only in the sales of the INVOcell system, but also in the greater revenue derived from the cycle procedures that would be performed to implement their solution.

INVO’s upcoming milestones include establishing more distributor & joint venture agreements and opening INVOcell only clinics in US (Atlanta, Birmingham & San Francisco Bay Area) and Mexico in 2021. INVO’s stated goal is to open of 3-5 INVO-only clinics in 2021 with existing partners in the U.S. and abroad, making progress with existing relationships the various countries.

INVO is also seeking to successfully receive the nod from the FDA for 5-day labelling, which alone would allow INVO to achieve a milestone payment of $3 Million from their U.S. partner Ferring Pharmaceuticals and is believe to further cement their place at the table when physicians are presented with infertility patients. This FDA nod may lead to a further expansion of the devices availability in the US. Indeed, it is believed that the OBGYN community (~20,000 in US) would begin to consider adopting the procedure within their own offices. Many believe that OBGYN’s are the ideal implementers of the INVOcell solution as they are in the first line in treating women and they could implement within the same office footprint that they already use on a daily basis thus increasing the access to affordable care not only in the major metropolitan ares but rural alike.

Click Here To Learn More About INVO Bioscience (INVO) & the world’s only in vivo Intravaginal Culture System (IVC), INVOcell®!